Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02775903
Title An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine

Azacitidine + Durvalumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.